Home » Targacept Begins Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes
Targacept Begins Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes
Targacept, Inc. Wednesday announced the initiation of separate Phase II clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
StreetInsider
StreetInsider
Upcoming Events
-
07May
-
14May
-
30May